30524966|t|A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.
30524966|a|Acute myeloid leukemia (AML) remains a challenging pediatric and adult disease. Given the elevated expression of the CD33 antigen on leukemic blasts, therapeutic approaches to AML now feature the approved antibody drug conjugate (Mylotarg, GO) and investigational CART cell approaches incorporating CD33-binding domains derived from humanized scFvs. We designed a functional chimeric antigen receptor utilizing a human targeting sequence, derived from a heavy chain variable domain, termed CAR33VH. Lentiviral-based expression vectors which encoded CAR constructs incorporating the novel binding domain (CAR33VH), or the My96 scFv control binder (My96CAR) in frame with a CD8 hinge and transmembrane domain, a 4-1BB costimulatory domain and a CD3 zeta activation domain, were transduced into primary human CD4+ and CD8+ T cells, and CAR expression was confirmed by flow cytometry. CAR33VH, similar to My96CAR, demonstrated robust and specific cytotoxicity in short-term and long-term co-incubation killing assays against CD33+ AML lines. In overnight cytokine release assays in which CAR T cells were challenged with the CD33+ tumor cells HL-60, MOLM-14 and KG-1a, CAR33VH elicited IFN-gamma, TNF-alpha and IL-2. This was seen with CD33+ cell lines, but not when CAR T were cultured alone. Studies with a CD33- cell line engineered to stably express the full length CD33 variant 1, or the naturally occurring CD33 splice variant 2, revealed that both CAR33VH and My96CAR, target the V domain of CD33, suggesting a similar therapeutic profile. Colony-formation assays utilizing peripheral blood CD34+ hematopoietic stem cells treated with CAR33VH, My96CAR, or with an untransduced T cell control, yielded similar numbers of BFU-E erythroid and CFU-GM myeloid colonies, suggesting a lack of CAR-related overt toxicity. In an in vivo AML model, NSG mice engrafted with MOLM-14 cells stably expressing firefly luciferase, both CAR33VH and CARMy96 efficiently eliminated tumors. In conclusion, we demonstrate for the first time the feasibility and efficacy of employing human variable domain-only binder derived from a phage display library in an anti-AML CAR design. CAR33VH, comprised of a human heavy-chain variable fragment-only antigen binding domain, was efficient in tumor killing in vitro and in vivo, and showed comparable functionality to the scFv-based My96CAR.
30524966	9	14	Human	Species	9606
30524966	63	67	CD33	Gene	945
30524966	68	71	CAR	Gene	653108
30524966	93	115	Acute Myeloid Leukemia	Disease	MESH:D015470
30524966	117	139	Acute myeloid leukemia	Disease	MESH:D015470
30524966	141	144	AML	Disease	MESH:D015470
30524966	234	238	CD33	Gene	945
30524966	250	258	leukemic	Disease	MESH:D007938
30524966	293	296	AML	Disease	MESH:D015470
30524966	416	420	CD33	Gene	945
30524966	530	535	human	Species	9606
30524966	666	669	CAR	Gene	653108
30524966	721	728	CAR33VH	Chemical	-
30524966	764	771	My96CAR	Chemical	-
30524966	789	792	CD8	Gene	925
30524966	860	868	CD3 zeta	Gene	919
30524966	917	922	human	Species	9606
30524966	923	926	CD4	Gene	920
30524966	932	935	CD8	Gene	925
30524966	950	953	CAR	Gene	653108
30524966	998	1005	CAR33VH	Chemical	-
30524966	1018	1025	My96CAR	Chemical	-
30524966	1060	1072	cytotoxicity	Disease	MESH:D064420
30524966	1138	1142	CD33	Gene	945
30524966	1144	1147	AML	Disease	MESH:D015470
30524966	1201	1206	CAR T	Gene	9607
30524966	1238	1242	CD33	Gene	945
30524966	1244	1249	tumor	Disease	MESH:D009369
30524966	1256	1261	HL-60	CellLine	CVCL:0002
30524966	1263	1270	MOLM-14	CellLine	CVCL:7916
30524966	1275	1280	KG-1a	CellLine	CVCL:1824
30524966	1282	1289	CAR33VH	Chemical	-
30524966	1299	1308	IFN-gamma	Gene	3458
30524966	1310	1319	TNF-alpha	Gene	7124
30524966	1324	1328	IL-2	Gene	3558
30524966	1349	1353	CD33	Gene	945
30524966	1380	1385	CAR T	Gene	9607
30524966	1422	1426	CD33	Gene	945
30524966	1483	1487	CD33	Gene	945
30524966	1526	1530	CD33	Gene	945
30524966	1568	1575	CAR33VH	Chemical	-
30524966	1580	1587	My96CAR	Chemical	-
30524966	1612	1616	CD33	Gene	945
30524966	1711	1715	CD34	Gene	947
30524966	1755	1762	CAR33VH	Chemical	-
30524966	1764	1771	My96CAR	Chemical	-
30524966	1840	1845	BFU-E	CellLine	CVCL:Z894
30524966	1906	1909	CAR	Gene	653108
30524966	1924	1932	toxicity	Disease	MESH:D064420
30524966	1948	1951	AML	Disease	MESH:D015470
30524966	1963	1967	mice	Species	10090
30524966	1983	1990	MOLM-14	CellLine	CVCL:7916
30524966	2083	2089	tumors	Disease	MESH:D009369
30524966	2182	2187	human	Species	9606
30524966	2264	2267	AML	Disease	MESH:D015470
30524966	2268	2271	CAR	Gene	653108
30524966	2280	2287	CAR33VH	Chemical	-
30524966	2304	2309	human	Species	9606
30524966	2386	2391	tumor	Disease	MESH:D009369
30524966	Bind	653108	925
30524966	Association	MESH:D015470	945
30524966	Association	945	9607
30524966	Negative_Correlation	MESH:D015470	653108
30524966	Association	MESH:D007938	945
30524966	Positive_Correlation	653108	919

